GURUFOCUS.COM » STOCK LIST » USA » NAS » VistaGen Therapeutics Inc (NAS:VTGN) » Definitions » Growth Rank
Switch to:

VistaGen Therapeutics Growth Rank

: 0 (As of Today)
View and export this data going back to 2011. Start your Free Trial

VistaGen Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


VistaGen Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


VistaGen Therapeutics Business Description

VistaGen Therapeutics logo
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Executives
Adler Reid G. officer: CHIEF LEGAL OFFICER C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94090
Fitzpatrick Margaret M director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94080
Rotunno Mary L. director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94090
Curley Joanne director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Ginski Mark J officer: SENIOR VP, HEAD OF CMC 12119 CECILIA CT KINGSVILLE MD 21087
Cunningham Ann Michelle director 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Mcpartland Mark A. officer: VP Corporate Development C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan officer: CHIEF MEDICAL OFFICER 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B director 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Dotson Jerrold Duane officer: ACTING CFO 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Underdown Brian J. director C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Bonfiglio Gregory A. director 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Rice A. Franklin officer: CHIEF FINANCIAL OFFICER 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Cato Allen Easley 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713

VistaGen Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)